Tuftsin analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
| Property | Value | Notes |
|---|---|---|
| Dry storage temperature | -20 C or below | Sealed, desiccated, protected from light |
| Solution stability | Hours to days at 2-8 C | Depends on buffer and microbial load |
| Preferred pH range | Near neutral to slightly acidic | Alkaline pH accelerates hydrolysis |
| Main degradation routes | Hydrolysis and deamidation | No cysteine or methionine in sequence |
| Identity confirmation | Electrospray mass spectrometry | Observed mass compared with 751.9 Da |
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
=== Chronic wounds === Any wound which is arrested or delayed during any of the normal stages of wound healing is considered to be a chronic wound. Most commonly, these are wounds which develop due to an underlying disease process such as diabetes mellitus or arterial/venous insufficiency. However, any acute wound has the potential to become a chronic wound if any of the normal stages of wound healing are interrupted. Chronic wounds are most commonly a result of disruption of the inflammatory phase of wound healing, however errors in any phase can result in a chronic wound. The exact duration of time which distinguishes a chronic wound from an acute wound is not clearly defined, although many clinicians agree that wounds which have not progressed for over three months are considered chronic wounds.
Drugs may be modified to be slowly activated by the body, or be absorbed slowly by the body. Many are dissolved in an organic oil, as the compound is lipophilic due to the addition of functional groups to provide slow action. An example of this is adding a functional group such as decanoate. The combination of an oil base and modification to decrease metabolic activation prevent medications from being fully released. This can result in length of activity of 2–4 weeks or more. The alteration of the pharmacokinetics of the drug (the absorption and activation) does not change the side effect profile of the medication; thus, atypical antipsychotics are still preferred over typical antipsychotics.
On average, groups of people with "obese" BMIs may have a higher risk of developing illnesses like diabetes, hypertension, dyslipidemia (high cholesterol), liver disease, and some cancers. "Underweight" BMIs may indicate malnutrition or other health problems. However, BMI has limitations when used to describe individual health rather than describing populations of people.
Free-flow electrophoresis (FFE) is a carrier-free electrophoresis technique that allows preparative protein separation in a laminar buffer stream by using an orthogonal electric field. By making use of a pH-gradient, that can for example be induced by ampholytes, this technique allows to separate protein isoforms up to a resolution of < 0.02 delta-pI.
== Preparation == The highly basic character of caricain makes it relatively easy to separate from the other papaya cysteine endopeptidases in cation-exchange chromatography of preparations of commercially available papaya latex. A sodium acetate gradient, pH 5.0, was first used successfully by Robinson and has since been adopted by others. Caricain is found in the latest-eluting protein peak. Due to the charge heterogeneity of caricain the peak may not be symmetrical, but this does not necessarily indicate the presence of contaminants. Covalent chromatography on thiol-Sepharose allows isolation of fully active caricain from the material obtained by cation exchange.
Sources: en.wikipedia.org
== Mobile phase == The mobile phase is composed primarily of supercritical carbon dioxide, but since CO2 on its own is too non-polar to effectively elute many analytes, cosolvents are added to modify the mobile phase polarity. Cosolvents are typically simple alcohols like methanol, ethanol, or isopropyl alcohol. Other solvents such as acetonitrile, chloroform, or ethyl acetate can be used as modifiers. For food-grade materials, the selected cosolvent is often ethanol or ethyl acetate, both of which are generally recognized as safe (GRAS). The solvent limitations are system and column based.
While interest in the study of mummies dates as far back as Ptolemaic Greece, most structured scientific study began at the beginning of the 20th century. Prior to this, many rediscovered mummies were sold as curiosities or for use in pseudoscientific novelties such as mummia. The first modern scientific examinations of mummies began in 1901, conducted by professors at the English-language Government School of Medicine in Cairo, Egypt. The first X-ray of a mummy came in 1903, when professors Grafton Elliot Smith and Howard Carter used the only X-ray machine in Cairo at the time to examine the mummified body of Thutmose IV. British chemist Alfred Lucas applied chemical analyses to Egyptian mummies during this same period, which returned many results about the types of substances used in embalming. Lucas also made significant contributions to the analysis of Tutankhamun in 1922. Pathological study of mummies saw varying levels of popularity throughout the 20th century. In 1992, the First World Congress on Mummy Studies was held in Puerto de la Cruz on Tenerife in the Canary Islands. More than 300 scientists attended the Congress to share nearly 100 years of collected data on mummies. The information presented at the meeting triggered a new surge of interest in the subject, with one of the major results being the integration of biomedical and bioarchaeological information on mummies with existing databases. This was not possible prior to the Congress due to the unique and highly specialized techniques required to gather such data.
=== Cardiometabolic index === The Cardiometabolic Index (CMI) estimates risk of type 2 diabetes, non-alcoholic fatty liver disease, and metabolic issues from waist-to-height ratio and triglycerides-to-HDL-C ratio. CMI has also been explored alongside cardiovascular disease and erectile dysfunction. Anti-inflammatory dietary patterns may improve related markers.
== Antimicrobial peptides == Antimicrobial Peptides (AMPs) have gained attention because they are much less susceptible to the development of microbial resistance. Other antibiotics may be susceptible to bacterial resistance, like multi-resistant staphylococcus aureus (MRSA) which is known as a common relic in the healthcare industry while other bacterial strains have become more of a concern for waste water treatment in local rivers or bays. AMPs can be functionalized onto a surface by either chemical or physical attachment. AMPs can be physically attached by using oppositely charged polymeric layers and sandwiching the polypeptide between them. This may be repeated to achieve multiple layers of AMPs for the recurring antibacterial activity. There are a few drawbacks to this mechanism. Assembly thickness and polymer-peptide interactions can affect the diffusion of peptide to bacterial contact. Further research should be carried out to determine the effectiveness of the adsorption technique. However, the chemical attachment of AMPs is also widely studied. AMPs can be covalently bound to a surface, which minimizes the "leaching effect" of peptides. The peptide is typically attached by a very exergonic chemical reaction, thus forming a very stable antimicrobial surface. The surface can be functionalized first with a polymer resin such as polyethylene glycol (PEG). Recent research has focused on producing synthetic polymers and nanomaterials with similar mechanisms of action to endogenous antimicrobial peptides.
Sources: en.wikipedia.org
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.
Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.
Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.